VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Viridian Therapeutics, Inc.\DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$20.80+1.77 (+9.30%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Gross margin
–
Operating margin
-512.9%+9999.5 pts over 5 years
Net margin
-483.6%+10060.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +23359.9% | +241.9% | +132.2% | +39.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 32.2% | -163.1% | -49.2% | |
| Return on assets | -91.7% | -137.1% | -41.7% | |
| Current ratio | 3.47 | 12.14 | 12.65 | |
| Debt to equity | -0.05 | 0.00 | – | |
| Net debt to EBITDA | 1.16× | 0.42× | – | |
| Interest coverage | -178.8× | – | -73.4× | |
| Capex to revenue | 7.2% | 4.0% | 0.7% | |
| Diluted shares | 0M | 4M | – |
Where the cash went
Fiscal 2021 to 2025, five years combined
Viridian Therapeutics, Inc.\DE generated $841.30M from operations and spent $3.04M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$841.30M
Used
$3.04M
Capital expenditure$3.04M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-483.6%
×Asset turnover0.09×
×Equity multiplier1.18×
=Return on equity, FY2025-49.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -483.6% | 0.09× | 1.18× | -49.2% |
| FY2024 | -89387.1% | 0.00× | 1.11× | -48.5% |
| FY2023 | -75711.5% | 0.00× | 1.11× | -56.8% |
| FY2022 | -7329.2% | 0.01× | 1.10× | -44.6% |
| FY2021 | -2680.2% | 0.02× | 1.09× | -51.6% |
| FY2020 | -10544.3% | 0.01× | 1.19× | -163.1% |
| FY2019 | -938.6% | 0.09× | 1.44× | -124.8% |
| FY2018 | -390.0% | 0.14× | 1.32× | -72.8% |
| FY2017 | -662.3% | 0.10× | -3.30× | 226.5% |
| FY2016 | -496.8% | 0.18× | -0.35× | 32.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$342.60M
- Cash generatingOperating cash flow above zero-$276.39M
- Return on assets improvedROA up on the prior year-55.0% → -46.1%
- Earnings backed by cashOperating cash flow above net income-$276.39M vs -$342.60M
- Less leverageLong-term debt to assets fell2.8% → –
- Better liquidityCurrent ratio rose15.43 → 12.65
- No dilutionShare count did not rise– → –
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.10